Kerna Labs
Kerna Labs (Kerna Laboratories Inc.) is a San Francisco AI biotech founded in 2024 by veterans of Deep Genomics and Moderna.
About
Kerna Labs (Kerna Laboratories Inc.) is a San Francisco AI biotech founded in 2024 by veterans of Deep Genomics and Moderna. It builds RNA foundation models and AI-driven sequence design to engineer next-generation mRNA therapeutics, targeting protein expression, tissue-specific delivery and manufacturability.
Capital graph
Founders / team· 4
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Kerna Labs
Kerna Labs (Kerna Laboratories Inc.) is a San Francisco AI biotech founded in 2024 by veterans of Deep Genomics and Moderna. It builds RNA foundation models and AI-driven sequence design to engineer next-generation mRNA therapeutics, targeting protein expression, tissue-specific delivery and manufacturability.
$6M
$6M
United States
BusinessLatest roundTotal raisedDate- RyboDyn
AI-driven sequencing and discovery platform decoding the "dark proteome" to find cancer-specific cryptic targets in patient tumors that conventional methods miss, for first-in-class cancer immunotherapies
Seed · $14M · 2026-03
$14M - Noetik
AI-based drug discovery, cancer immunology
Seed · $14M · 2023-09
$14M - Tamarind Bio
No-code computational biology platform combining AI and physics models for molecular structure design/analysis
Series A · $14M · 2026-03
$14M
China
BusinessLatest roundTotal raisedDate- Levinthal Biotech
AI protein design services, with the proprietary all-atom protein design platform Pallatom
Series A · $14M · 2025-12
$14M - LattixOrigin
Cross-scale human brain foundation model for drug target discovery in neurodegenerative diseases
Seed · 2026-10
— - AIPher
AI-native drug discovery: proprietary drug foundation models and AI agent engine for early discovery of novel small-molecule, peptide and other drugs
Angel · 2026-09
—
Europe
BusinessLatest roundTotal raisedDate- Sightera Biosciences
AI-native drug discovery: patient-derived disease models and generative AI to design small-molecule cancer/fibrosis therapies
Pre-Seed · $3M · 2026-07
$3M - Cyclana Bio
Tissue-level drug discovery model for treating endometriosis
Pre-Seed · $7M · 2025-10
$7M - CardiaTec
Uses AI and large-scale multi-omics data to discover new therapies for cardiovascular disease
Seed · $7M · 2024-09
$7M
Other / unspecified
BusinessLatest roundTotal raisedDate- 深度细胞
Combines AI with multiscale molecular physics to build a "virtual cell world model" for disease mechanism discovery and drug design
Seed · $14M · 2026-08
$14M - Mana.bio
Uses AI to design lipid nanoparticles for delivering mRNA to specific parts of the body
Seed · $20M · 2023-10
$20M - Halmos Labs
AI-driven automated R&D systems for biotech and pharma that simulate experimental outcomes before wet-lab work and recommend the experiments that most reduce uncertainty
—
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 22 in Silicon Valley
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.